Please login to the form below

Not currently logged in
Email:
Password:

EU drops Boehringer Ingelheim patent probe

The EU has closed antitrust investigations regarding Boehringer Ingelheim's COPD drugs

The European Union has dropped an antitrust investigation into Boehringer Ingelheim's patents for chronic obstructive pulmonary disease (COPD) treatments.

The decision came as German firm Boehringer Ingelheim agreed to remove "blocking positions" that Spanish rival Almirall alleged prevented sales of its treatments for COPD.

In addition, the EU's antitrust agency said pharmaceutical companies struck only three “problematic” patent- settlement deals in 2010 that may be used to delay the sale of generic versions of medicines.

Joaquín Almunia, commission vice president in charge of competition policy, said: "I note with satisfaction that the number of patent settlements potentially problematic under EU antitrust law continues to decrease without calling into account companies' legitimate right to settle disputes amicably.

"The commission will remain vigilant that companies' behaviour respect antitrust law and do not delay entry of cheaper pharmaceuticals," he added.

7th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics